Introduction {#s0005}
============

RA is an autoimmune disease that causes chronic inflammation of the joints and other areas of the body. RA is characterized by periods of disease development and attenuation. RA tends to affect multiple joints usually, but not always, in symmetrical patterns [@b0005].

The US and UK populations are affected by RA disease with 1% approximately. In some other ethnicities, such as China, Japan and some black populations in rural South Africa, assessment of the spread of the disease is as low as 0.2--0.3%. The affected women are approximately twice the affected men. It most often starts within the range of 45--55 years of age [@b0010].

The precise etiology of RA has not been established yet. The cause of RA is a very active area of the worldwide research. It is believed that the tendency to develop RA may be genetically inherited. Also, environmental factors, such as smoking tobacco, may cause the malfunction of the immune system in susceptible individuals [@b0015].

There is no singular test for diagnosing RA. Instead, RA diagnosis is based on a combination of (1) the presentation of the joints involved, (2) the characteristic joint stiffness in the morning, (3) positive rheumatoid factor (RF) and citrulline antibody, and (4) the findings of rheumatoid nodules and radiographic changes. There is no known specific cure for RA. To date, the goal of treatment in RA is to (a) reduce joint inflammation and pain, (b) maximize joint function, and (c) prevent joint destruction and deformity. Treatment is customized according to many factors such as disease activity, types of joints involved, general health, age, and patient's occupation.

The first-line of drug treatment, such as cortisone, is used to reduce pain and inflammation in RA patients. The disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate, promote disease remission and prevent progressive joint destruction. In some cases with severe joint deformity, surgery may be necessary [@b0020].

Biological drugs which are considered other kinds of DMARDs, offer more specific action and provide clues to other biological pathways and biomarkers. They work on the immune system and block signals that lead to inflammation. For example, (etanercept, infliximab, and adalimumab) block tumor necrosis factor alpha (TNFα) which is an important player in RA. A test, predicting the response to anti-TNFα treatment, would be an important tool to rheumatologists. This test will reduce the deterioration of the patient and save time and money by defining the most effective biological drug before its usage [@b0025].

Due to the extremely increase in the diseases, re-characterization of disease in pathological and physiological terms using biomarkers is a turn to the future of medicine. A biomarker is defined as any parameter that can be objectively examined and measured as a marker of (a) normal biological processes, (b) pathogenic processes, or (c) pharmacological response to a therapeutic intervention. These indicators could include a wide range of biochemical materials, such as nucleic acids, proteins, sugars, lipids, and metabolites, as well as whole cells or biophysical characteristics of tissues. Detection of biomarkers, either individually or as larger sets or patterns, can be accomplished by a wide variety of methods, ranging from biochemical analysis of blood or tissue samples to biomedical imaging [@b0030].

SNPs are considered as the most common type of sequence variation in genomes. Most commonly, SNPs can serve as valuable genetic biomarkers; guiding biologists in detecting genes that are related to common diseases [@b0035]. In this review, the SNPs were used as biomarkers for detecting RA. The variation in these nucleotides has higher frequency in affected people than in normal individuals. Most of these nucleotides are located within genes or near genes. Most of those genes are involved in immune regulation. As RA is an autoimmune disease, so those genes suggest an important set of processes involved in RA pathogenesis [@b0040].

Genome-wide association studies (GWAS), using SNPs, have marked a collection of genes that may be associated with RA susceptibility, especially the genes that encode immunoregulatory factors [@b0045]. TNFα is a part of the immunopathogenesis and an early stage biomarker for RA. It is reasonable to assume that TNFα levels are elevated long before the appearance of symptoms on the patient [@b0025]. [Fig. 1](#f0005){ref-type="fig"} shows a historical view of RA genetic biomarkers until 2010. *HLA* (human leukocyte antigen)*-DR4* and shared epitope (*SE*) (multiple alleles at the *HLA--DRB1* locus) represent approximately 15% of RA disease risk factors. The last decade reflects enormous growth in RA biomarker findings [@b0050].

Haplotype block {#s0010}
===============

Linkage Disequilibrium (LD) specifies that the nearer alleles that coexist on the same chromosome tend to be linked to each other. The alleles that are far away from each other are more likely to take place by chance, since the recombination events between such alleles are more likely. The target of association mapping is defining alleles that raise the susceptibility to a disease. These alleles are more frequent among cases than among controls. The SNP associated with a disease (risk or protective) is an evidence for the association of its region with the disease. So, the LD patterns are very useful for the identification of other indirect SNPs at the same region.

If two alleles that coexist on the same chromosome are linked to each other, then a deviation (*D*) will be presented in the observed frequencies from the expected frequencies. (*D*) is one of the most common measures of LD [@b0055]. Other two valuable measures of LD are correlation coefficient (*r*^2^) and normalized deviation (*D*′). (*r*^2^) takes a value from zero to one reflecting the strength of association between pairs of alleles. Generally speaking, the strength of association between SNPs decreases as the genetic distance between these SNPs increases. The perfect LD quantitatively means (*r*^2^ = 1) [@b0060]. The strong LD has a (*r*^2^) cut-off of 0.8 as generally seen in published papers [@b0065], [@b0070], [@b0075].

The recent sequencing/genotyping technologies allow completely sequencing large DNA segments or genotyping millions of SNPs. However, the presence of LD between SNPs allows reducing the number of genotyped SNPs and, therefore, reducing also the cost of the association study without a significant loss in the power of association [@b0035].

Some studies on different genes of the human genome showed that the structure of the human genome is blocky in nature [@b0080]. The observations of experiments concluded that many chromosomes have blocky patterns [@b0085]. The existence of that blocky structure has a great advantage to the association studies. Haplotype blocks contain the structure of LD in the human chromosomes. These blocks describe the SNP pattern using a somewhat uncomplicated scheme. The main properties of the haplotype block are: (a) the reduced haplotype diversity within the block; (b) absence or very low number of recombination events inside the block i.e. high LD; (c) recombination events present between blocks i.e. low LD [@b0090]. Although recombination events are usually at the boundaries of the haplotype blocks, a homogenous recombination region will deceivingly look like a blocky pattern of haplotypes. The relationship between any SNP in the blocky pattern and all the other SNPs in the same pattern is statistically significant; as any SNP contributes to the whole block. A reduced set of tagging SNPs can be used to identify all observed haplotypes instead of analyzing all SNPs within the block [@b0095].

Block extent varies greatly with different ethnicities. Depending on this information, the US Nat'l Human Genome Research Institute (USNHGRI) has started an extensive endeavor, called the Int'l HapMap Project in 2002. This project intended to construct a genome-wide map of LD and haplotype blocks among populations. The sampled populations were from European, Asian, and African ancestries. Four countries provided the 270 DNA samples for HapMap project which are US, Japan, China, and Nigeria. The US provided samples of 30 trios (two parents and one adult child) from Utah residents of European ancestry. Japan provided samples of 45 unrelated residents from Tokyo area. Beijing, China provided 45 samples of unrelated Han Chinese. Nigeria provided samples of 30 trios from the Yoruba people of Ibadan. The number of genotyped SNPs is more than one million SNPs with 5 kb (kilo base) inner intervals [@b0540].

The 1000 Genomes Project was launched in 2008. The aim of the project was to identify the genetic variants that have at least 1% allele frequencies in the studied populations. The studied populations were East Asians, South Asians, Africans, Europeans, and Americans. Researchers could benefit from the identified variants by relating them to diseases through association studies. Also, the project targeted the haplotype background and LD patterns of the variant alleles [@b0105].

The challenge of segmenting the genome into blocks of low haplotype diversity is called haplotype block partitioning. The main haplotype block partitioning methods are the four gamete test (FGT) [@b0110] and the confidence interval test (CIT) [@b0115]. There are other approaches to partition haplotype blocks such as solid spine of LD [@b0120], hidden markov model [@b0125], [@b0130], dynamic programming-based algorithm [@b0135], [@b0140], [@b0145], wavelet decomposition [@b0150], greedy algorithm [@b0155], minimum description length [@b0160], [@b0165], and block entropy [@b0170].

The target of haplotype block partitioning is to decrease the complexity of association mapping so as to deal with haplotype blocks instead of individual SNPs. Other important applications of haplotype block partitioning are SNPs tagging, post-GWAS SNP-set analysis, SNPs-to-gene mapping [@b0175].

Haplotype blocks vs individual SNPs {#s0015}
===================================

Individual SNP approaches accomplished impressing findings in case of monogenic diseases (such as cystic fibrosis). On the other hand, they did not reach the same success in complex diseases (such as type I diabetes mellitus). Haplotype blocks may capture interaction between SNPs (SNPs that contribute to the disease status together but not separately), which is not possible with individual-SNP tests [@b0175]. Using individual SNP approaches expands the dimension of association testing. While using haplotype block methods reduces it with ensuring reasonable error rates. So, the haplotype block methods are expected to increase the power of association more than the individual SNP approaches. The drawbacks of haplotype blocks methods, (a) haplotype data are more expensive to collect than genotype data; (b) phase (i.e. haplotype) estimation, where the phase of SNPs can be homozygous or heterozygous; (c) different haplotype block methods lead to different haplotype blocks resulting in a problematic decision making in choosing the best method for association mapping; (d) if the number of haplotypes inside a block increases, the degree of freedom of the block increases resulting in reduced power; (e) applying statistical procedures ends up with computational error. Some studies debated that individual SNPs will have at least the same power of association as haplotype blocks. Experimental results showed unclear conclusions in this debate. The contradictory findings support that the performance of the methods may depend on the nature of the studied data.

Shim et al. [@b0180] aimed to measure the power of association of the two strategies: the individual SNP approaches and the haplotype block methods. They used a dataset from the North American RA Consortium (NARAC) provided by the Genetic Analysis Workshop 16 (GAW16). They tested 513,935 SNPs in 868 cases and 1194 controls. The examined haplotype block methods were FGT and CIT implemented using Haploview program. Haplotype block methods had lower *p*-values than individual SNP approaches. A low *p*-value means that the probability of observing these results by chance is very small. Haplotype block methods reduced the no. of the required tests using individual SNP approaches by a factor of about 0.65.

Some biomarkers were detected by haplotype block methods only. This may be due to the higher ability of haplotype block methods for detecting rare alleles. Other biomarkers were detected by individual SNP approaches only. This may be because of the neighboring SNPs, to the causal SNP in the block, having weakened the strength of the association. Finally, they suggested the use of the two strategies to maximize the detection of RA biomarkers.

RA biomarkers {#s0020}
=============

The main biomarkers that have been considered as risk factors for RA are within the major histocompatibility complex (MHC) region which is positioned on chromosome 6 (6p21.3). The HLA region within the MHC contributes to almost 50% of the genetic susceptibility for RA. Other RA biomarkers outside the MHC region are also considered significant [@b0185], [@b0190].

Biomarkers in the MHC region or chromosome 6 {#s0025}
--------------------------------------------

The MHC region is highly related to autoimmune diseases. This relation has been shown through many association mapping studies. The MHC region extends over 3.6 Mb, as shown in [Fig. 2](#f0010){ref-type="fig"}. The MHC region contains about 220 genes, many of which have immunoregulatory functions [@b0195].

HLA--DR4 and *HLA--DRB1* genes are highly associated with RA. The *HLA--DRB1* associations are intensely detected in the anti-CCP + (anti-cyclic citrullinated peptide positive) antibodies group [@b0200]. TNF locus is one of the most studied loci in the MHC region. TNF locus is located inside the MHC class III region, about 1000 kb from *HLA--DRB1* [@b0195].

HLA locus is associated with RA disease in multiethnic populations. Muazzam et al. [@b0205] confirmed the haplotype association of *DRB1* and *DQB1* variants of HLA class II with RA in Pakistani population. Atouf et al. [@b0215] verified that *HLA--DRB1∗04* allele predisposed to RA, while *HLA--DRB1∗07* allele had a protective role in Moroccan population. Al-Swailem et al. [@b0220] provided that *HLA--DRB1∗04* prevailed *∗08* and *∗10* alleles in association with RA, while *DRB1∗06* allele seemed protective to RA in Saudi Arabian population. Ucar et al. [@b0225] confirmed the association of RA *with HLA--DRB1∗01*,*∗04*, and *∗09* alleles, whereas *∗13* was the protective allele against RA in Eastern Black Sea Turkish population.

Mourad and Monem [@b0230] detected the association of Syrian RA patients with *HLA--DRB1∗01*, *∗04*, and *∗10* alleles, while *∗11* and *∗13* were the protective alleles against RA. Ben Hamad et al. [@b0235] indicated that *HLA--DRB1∗04*, and *∗10* alleles are related with RA, while patients harboring *DRB1∗08* allele had a decreased risk of developing RA in the Southern Tunisian population. HLA alleles had been verified in many populations [@b0240], [@b0245], [@b0250], [@b0255], [@b0260], [@b0265], [@b0270], [@b0275], [@b0280], [@b0285], [@b0290], [@b0295], [@b0300], [@b0305], [@b0310], [@b0315], [@b0320].

Ding et al. [@b0200] identified other risk loci in the MHC region. They studied RA patients in two risk groups, defined according to the presence or absence of ACPA. They refined *DRB1* common variants, and detected additional associations with alleles near *HLA--DPB1* for ACPA-positive RA patients, as shown in [Fig. 3](#f0015){ref-type="fig"}. For ACPA-negative RA patients, they did not find any linkage with alleles within the MHC region.

Lee et al. [@b0325] provided supplementary risk loci for RA in the MHC region, separated from the class II *HLA*--*DRB1* locus. This research suggested the existence of two regions of association with RA in the class I region. *HLA-C* locus was associated with RA (*P* ∼ 5 × 10^−5^). In addition, alleles located near the *ZNF311* (zinc finger protein 311) locus were detected.

A known risk variant at the *TAGAP* (T cell activation RhoGTPase activating protein) gene locus represents a candidate, but not convincing, biomarker for association with RA susceptibility. Chen et al. [@b0330] refined the *TAGAP* risk locus. The SNP (rs212389) demonstrated a potent association with RA disease (P = 3.9 × 10^−8^). This risk locus prevailed overwhelmingly convincing upon the former RA SNP (rs394581, P = 2.2 × 10^−5^).

*NKAPL* (NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) activating protein-like) gene is 90% similar to *NKAP* gene. While *NKAPL* functions are still unknown, *NKAP* is a protein implicated in NF-kB-mediated transcriptional activation of *TNF* and *IL-1* (interleukin 1 family). Xie et al. [@b0335] fine-mapped the *NKAPL* gene to verify the association with RA disease. Fine-mapping analyses detected six SNPs in a single haplotype block in Canadian population. (rs35656932) in the *ZNF193* gene and (rs13208096) in the *NKAPL* gene showed the highest significance of association with RA susceptibility, and were replicated in the US cohort. By illustrating supplementary *NKAPL* alleles, the results confirmed the potent association between *NKAPL* and RA disease. These additional *NKAPL* variants were associated with variants located in *HLA--DRB1* locus. *NKAPL* variants and *HLA--DRB1* variants suggested a synergistic effect between the two regions.

Plenge et al. [@b0340] detected a SNP at 6q23 (rs10499194) approximately 150 kb from (*TNFAIP3* (TNF alpha-induced protein 3), telomeric) and approximately 185 kb from (*OLIG3* (oligodendrocyte transcription factor 3), centromeric), as shown in [Fig. 4](#f0020){ref-type="fig"}. In a parallel research, the Wellcome Trust Case Control Consortium (WTCCC) identified potent association of RA to a distinctive SNP (rs6920220) lied 3.8 kb from (rs10499194).

*TNFAIP3*, which encodes protein A20, is a strong terminator of the NF-kB signaling and is needed for inhibition of TNF-induced signals. TNFα levels are elevated in RA patients. Termination of TNFα is an effective treatment of severe RA. In addition, mice showing shortage in *TNFAIP3* present chronic inflammation. *TNFAIP3* plays a dominant role in autoimmunity. There is a lack of information about *OLIG3*. Mice, with mutation in *OLIG3*, have deficiencies in neuronal development. But, abnormalities are not recognized in the immune system or musculoskeletal system.

Biomarkers outside MHC region {#s0040}
-----------------------------

Association mapping studies have led to the detection of genetic biomarkers outside the MHC region. *PTPN22* (protein tyrosine phosphatase non-receptor type 22) is identified as the most statistically significant biomarker for RA disease outside the MHC region in populations of European ancestry. *TRAF1-C5* (TNF receptor-associated factor 1 -- complement component 5) region comes next *PTPN22* in the significance of association with RA [@b0345].*PADI4* (peptidyl-arginine de-iminases_type 4) appears to have important association with RA in Asian populations. On the other hand, an association between RA and *PADI4* is not confirmed in Caucasian populations. These populations vary in environmental factors which may explain the previous results [@b0350].

Plenge et al. [@b0355] tested 17 SNPs from 14 genes in 2370 RA patients and 1757 controls from the NARAC and the Swedish Epidemiological Investigation of RA (EIRA) datasets. All cases and controls were of European descent. The association of *PTPN22* with ACPA-positive RA was confirmed. Also, an association with *CTLA4* (cytotoxic T-lymphocyte antigen 4) and *PADI4* was provided, but in NARAC dataset only. The results concluded that *PTPN22* is associated with not only RF-positive patients but also ACPA-positive patients. This conclusion was expected, providing the vigorous correlation between RF and CCP situation. Together, these findings gave the most powerful indication of a non-MHC region that influenced the susceptibility to RA.

*CD40* (cluster of differentiation 40) signaling plays a very important role in innate and adaptive immunity against microorganisms. *CD40* is a member of the *TNFR* (TNF receptor) family of genes and is expressed on B cells and antigen-presenting myeloid cells. *CD40* exists on chromosome region (20q13.1). Genetic studies on *CD40* showed an association with autoimmune diseases [@b0360].

Raychaudhuri et al. [@b0365] detected an allele at the *CD40* gene locus (rs4810485) which was susceptible for RA. This result showed that *CD40* was a critical player in RA pathogenesis. They also detected another variant at the *CCL21* (chemokine (C--C motif) ligand 21) gene locus (rs2812378). *CCL21* is a gene involved in immunoregulatory functions. Finally, they provided a proof of association at four supplementary gene loci: *MMEL1-TNFRSF14* (membrane metallo-endopeptidase-like 1 -- TNFR superfamily member 14) (rs3890745), *CDK6* (cyclin-dependent protein kinase 6) (rs42041), *PRKCQ* (protein kinase C theta type) (rs4750316), and *KIF5A-PIP4K2C* (kinesin family member 5A-phosphatidylinositol-5-phosphate 4-kinase, type II, gamma) (rs1678542).

Gregersen et al. [@b0370] performed a GWAS for RA disease patients from North America on a combined dataset of 2418 cases and 4504 controls. They provided an association at the *REL* (reticuloendotheliosis) locus, which encodes protein c-Rel, on chromosome region 2p13 (rs13031237, rs13017599). The combined dataset also identified other variants at *CTLA4* (rs231735) and *BLK* (B lymphocyte kinase) (rs2736340). c-Rel has biological activity effects on hematopoietic cells, and is an NF-kB family member. c-Rel was associated with RA providing disease tracks that included other known RA susceptibility genes such as *CD40*, *TRAF1*, *TNFAIP3* and *PRKCQ*.

Raychaudhuri et al. [@b0375] tested 22 susceptibility loci in a dataset of 7957 cases and 11,958 controls. Three loci were conclusively approved: (a) *CD2*--*CD58* (cluster of differentiation 2-cluster of differentiation 58) (rs11586238); (b) *CD28* (cluster of differentiation 28) (rs1980422); and (c) *PRDM1* (PR domain zinc finger protein 1) (rs548234). A supplementary four susceptibility genes were reproduced (*P* \< 2.3 × 10^−3^): *TAGAP* (rs394581), *PTPRC* (protein tyrosine phosphatase receptor type C) (rs10919563), *TRAF6--RAG1* (TRAF6-recombination activating gene 1) (rs540386) and *FCGR2A* (Fc fragment of IgG, low affinity IIa) (rs12746613). Many of these SNPs reveal some of the shared mechanism of RA pathogenesis as they are also associated with other immunologic diseases.

Kurreeman et al. [@b0380] applied a research plan on distinct populations to confirm the identification of universal RA risk loci. Thirteen known risk variants were tested in different sample sets consisting of overall 4366 cases and 17,765 controls of European, African American, Japanese, and Korean ethnicities. Two alleles (rs3890745 at the 1p36 locus) and (rs2872507 at the 17q12 locus) overstepped genome-wide significance in all 16,659 RA cases and 49,174 controls combined. They used GWAS data to refine these two alleles in Europeans and East Asians, and they confirmed risk association in both ethnic groups. A series of bioinformatics analyses identified *MMEL1--TNFRSF14* at the 1p36 locus and *IKZF3-ORMDL3-GSDMB* (IKAROS family zinc finger 3-ORM1-like 3-gasdermin B) at the 17q12 locus as the genes most likely associated with RA.

RA biomarkers in other diseases {#s0045}
-------------------------------

RA and celiac disease (CD) show shared mechanism of disease pathogenesis. They are two distinct autoimmune diseases with co-occurrence in families. GWAS verified the HLA region and 26 non-HLA genetic variants in each disease. Past studies confirmed six SNPs occurring in both diseases out of the 26 risk loci. Zhernakova et al. [@b0385] thought to enhance the definition of shared disease pathogenesis through identifying new risk loci. They performed a combined analysis of 50,266 samples. The study resulted in the identification of new four SNPs that were not previously verified in either disease: (a) the rs10892279 near the *DDX6* (DEAD (Asp-Glu-Ala-Asp) box helicase 6), (b) the rs864537 near *CD247* (cluster of differentiation 247), (c) the rs2298428 near *UBE2L3* (ubiquitin-conjugating enzyme E2L3), and (d) the rs11203203 near *UBASH3A* (ubiquitin associated and SH3 domain containing A). Four common variants associated in both diseases are confirmed: *SH2B3* (SH2B adaptor protein 3), 8q24, *STAT4*, and *TRAF1-C5*. These results involved genes responsible for immune functions such as antigen presentation and T-cell activation.

*KCNB1* (potassium voltage-gated channel, shab-related subfamily, member 1) is a candidate gene for association with RA disease. This candidacy comes from the important function of *KCNB1* in the immune system. Four identical *KCNB1* sub-units are the main components of the functional channel in human T lymphocytes. Autoimmune diseases such as type 1 diabetes mellitus and RA are medicated with several peptide inhibitor of *KCNB1*. Noticeable defect in potassium channels function involving *KCNB1* by autoimmune diseases had been confirmed. Xiao et al. [@b0390] examined the association between *KCNB1* and RA disease in GAW16 dataset. *KCNB1* showed moderate association with RA.

Chung et al. [@b0395] tested common variants associated with RA and GPA (granulomatosis with polyangiitis) (wegener's). They conducted a meta-analysis of GPA showing convincing association with risk loci in *CTLA4*. The studied risk alleles associated with RA were also significantly associated with GPA. RA and GPA may originate from a similar genetic tendency.

Some genes are risk variants for several autoimmune diseases. Li and Begovich [@b0400] stated that the risk variant *TNFAIP3* was the only one that had been recorded in both psoriasis and RA diseases. *TNFAIP3* had also been associated with SLE (systemic lupus erythematosus). These results showed that RA, SLE, and psoriasis may originate from a similar genetic predisposition. Also, *TNFAIP3* was confirmed to play a complex role in different autoimmune diseases.

Okada et al. [@b0405] conducted a GWAS for RA in a Japanese cohort. They confirmed strong association with RA disease at nine loci. The nine variants were as follows:(1)*B3GNT2* (UDP-GlcNAc: beta-1,3-N-acetylglucosaminyltransferase 2),(2)*ANXA3* (annexin A3),(3)*CSF2* (colony stimulating factor 2),(4)*CD83* (cluster of differentiation 83),(5)*NFKBIE* (NF-kB inhibitor, epsilon),(6)*ARID5B* (AT rich interactive domain 5B),(7)*PDE2A-ARAP1* (phosphodiesterase 2A-ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1),(8)*PLD4* (phospholipase D family, member 4) and(9)*PTPN2* (protein tyrosine phosphatase non-receptor type 2), as shown in [Fig. 5](#f0025){ref-type="fig"}.

*ANXA3* gene, associated with RA, was also associated with SLE. *B3GNT2* and *ARID5B* were associated with susceptibility to graves' disease.

RA biomarkers in children {#s0050}
-------------------------

RA is an autoimmune disease, generally affects people during middle age. Children with RF and/or ACPA-positive juvenile idiopathic arthritis appear like adults with RA disease, and represent the childhood onset of RA (CORA). Polymorphisms within HLA and many other genes were evaluated for RA risk susceptibility, but had not been investigated intensively in children. To provide evidence that RA risk alleles would also be connected to CORA, Prahalad et al. [@b0410] examined RA SNPs in large set of children with CORA. CORA was most frequent among children of 11 years, and 85% of studied cases were females. CORA and *HLA--DRB1* SNPs revealed a significant association as the situation in RA disease. Genetic studies showed a critical association between CORA and *TNFAIP3*, *PTPN22*, and *STAT4*.

Ezzat et al. [@b0415] studied the susceptibility of Egyptian children to juvenile rheumatoid arthritis (JRA) associated with *HLA--DRB1* locus. They provided that *HLA--DRB1∗04* and *∗14* prevailed *DRB1∗01* alleles in the association with JRA in a study of 60 cases and 50 controls. *HLA-DRB1∗08* allele seemed to be protective to JRA in Egyptian children.

Gender specific biomarkers {#s0055}
--------------------------

Caliz et al. [@b0420] performed a study to analyze alleles in *Th1* (T helper 1 cells) and *Th17* (T helper 17 cells) which are cell mediated immune response genes. They aimed to investigate whether the studied genes differently control RA susceptibility in females and males. Patients accommodating *Dectin-2* allele (rs4264222T) had a critical RA susceptibility, while *DC-SIGN* (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) allele (rs4804803G), *MCP-1* (monocyte chemotactic protein-1) allele (rs1024611G), *MCP-1* allele (rs13900T) and *MCP-1* allele (rs4586C) had a protective role against RA.*Dectin-2* allele (rs4264222T) and *Dectin-2* allele (rs7134303G) were associated with RA in females. *MCP-1* alleles (rs1024611G), (rs13900T), and (rs4586C) increased the immunization against RA in females. *DC-SIGN* allele (rs2287886A) was associated with RA in males. *DC-SIGN* allele (rs4804803G) played a protective role in RA in males.

They also concluded that *Dectin-2* SNPs (rs4264222) and (rs7134303) represented a potent two locus interaction model in females through SNP-SNP interaction analysis of significant SNPs. The last findings were not seen in men.

WTCCC detected a SNP (rs11761231), on chromosome 7q, which presented gender relationship. This SNP showed a critical association with RA susceptibility only in females in a British population. Korman et al. [@b0425] tested the same SNP in a North American population but failed to find any association of the 7q region with RA.

Biomarkers in different populations {#s0060}
-----------------------------------

Stahl et al. [@b0430] identified seven RA risk loci (*P* \< 5 × 10^−8^) in a study of all 41,282 samples from Canada, North America, Sweden, Netherlands, UK, and US. The associated variants were located close to genes of immunoregulatory functions, involving the following:(1)*IL6ST* (interleukin 6 signal transducer),(2)*SPRED2* (sprouty-related, EVH1 domain containing 2),(3)*RBPJ* (recombination signal binding protein for immunoglobulin kappa J region),(4)*CCR6* (chemokine (C--C motif) receptor 6),(5)*IRF5* (interferon regulatory factor 5),(6)*C5orf30* (chromosome 5 open reading frame 30), and(7)*PXK* (PX domain containing serine/threonine kinase).

They also enhanced associations at two RA common variants (*IL2RA* (interleukin 2 receptor, alpha) and *CCL21*) and verified the association at *AFF3* (AF4/FMR2 family, member 3).

Hughes et al. [@b0435] tested whether the validated RA SNPs among people of European ancestry are linked to RA risk loci in an African American population. Twenty-four of the 27 examined SNPs had been confirmed for the association with RA in the European and African American populations. On the contrary, the remaining 3 of the 27 SNPs (*CCR6*, *TAGAP*, and *TNFAIP3* (rs6920220)) failed to represent acceptable association with RA in African American population.

Eyre et al. [@b0440] tested 14 alleles, 5 of which were definitely associated with ACPA-positive RA patients and, 9 of which were associated generally with RA disease. The studied populations were from Canada, North America, Sweden, Spain, Netherlands, UK, and US. The genes involved in RA susceptibility in European descents in that study were shown in [Fig. 6](#f0030){ref-type="fig"}.

Many of the identified biomarkers of RA belong to Caucasian populations. Viatte et al. [@b0445] examined the association of Caucasian non-HLA alleles with RA patients in Black African populations. They found weak association between most of the SNPs and West/Central African population. RA susceptibility SNPs, grouped in a set of 28 Caucasian alleles, were highly distinct between the UK and Africa with (*p* \< 0.001). They concluded that the genetic risk variants of developing RA are different in Africans from Caucasians. Interestingly, these results confirmed that ethnic group had a great influence on the genetic architecture of RA susceptibility, forcing the researchers to identify the RA SNPs of each ethnic group separately.

Weak association between *PADI4* and RA susceptibility was noticed in Caucasian cohorts. *PADI4* was convincingly associated with RA disease in East Asian populations. Too et al. [@b0450] aimed to verify the association between *PADI4* and RA susceptibility in Malaysian, Chinese, Indians, and other populations from South East Asia. The results presented that *PADI4* and RA were associated in the multiethnic populations from South East Asia and provided supplementary association with *PADI2* risk locus. *PADI2* and *PADI4* genes contributed to enzymes responsible for citrullination. The results thus verified the association of RA with *PADI4* in multiple populations of Asian descent.

The *MTHFR* (Methylenetetrahydrofolate reductase) is a catalytic enzyme which plays an essential role in the conversion of 5,10-methylenetetra-hydrofolate to 5-methyltetrahydrofolate. 5-methyltetrahydrofolate helps in the conversion of methionine from homocystine in vitamin B~12~ dependent pathway. Homocysteine was recorded at high levels in RA patients. In further reactions, methionine is converted to S-adenosylmethionine. S-adenosylmethionine helps in nucleotide methylation in DNA, RNA, and proteins. The *MTHFR* gene is located on 1p36 region. The A1298C is a common polymorphism in the *MTHFR* gene. The A1298C was verified as a biomarker for RA disease in Jewish and Italian populations [@b0455], [@b0460]. Contradictory results were shown in American population with Caucasian and African ethnicities [@b0465]. The allele (*1298C*) was found to exhibit lower *MTHFR* enzyme activity, hyperhomocysteinemia, and decreased folate levels.

Okada et al. [@b0470] conducted a GWAS for RA in 29,880 cases and 73,758 controls of European and Asian ancestries. The total number of studied SNPs was nearly 10 million. They identified 42 novel risk loci for association with RA. The results of the study led to the expansion of the detected RA risk loci to 101. They also designed a systematic strategy to identify 98 biological candidate genes at these 101 risk loci. These genes should be targeted for RA drug discovery and further repurpose approved drugs for other diseases for RA treatment.

Haplotype blocks in RA biomarker discovery {#s0065}
==========================================

Suzuki et al. [@b0475] tested a haplotype block, consisted of 17 SNPs, for association with RA in *PADI4* gene. Expectation maximization method was used to detect the haplotypes that were expected to have a frequency of more than 0.02 in both patient and healthy individual groups. Four haplotypes, out of 217 possible haplotypes, fulfilled the condition. The most redundant haplotype (haplotype 1) and the second most redundant haplotype (haplotype 2) together represented more than 85% of the observed haplotypes in both groups. Haplotype 1 was mainly detected in healthy individuals and was called the non-susceptible haplotype. Haplotype 2 was mainly detected in patients and was called the susceptible haplotype. Next, they aimed to test the haplotypes affecting the stability of *PADI4* mRNA. They concluded that susceptible mRNA had higher stability than non-susceptible mRNA. Furthermore, the susceptible haplotype was associated with higher levels of antibody to citrullinated peptide in patients' sera.

Ikari et al. [@b0480] tested a haplotype block within *PTPN22* gene, consisted of 8 SNPs spanning 45 kb, for association with RA in Japanese population. Expectation maximization method was used to detect the haplotypes that were expected to have a frequency of more than 0.01 in the studied groups. Finally, they did not detect any association with RA in Japanese population.

Plenge et al. [@b0485] tested a haplotype block in *PHF19* (PHD finger protein 19)*-TRAF1-C5* region, containing nine tag SNPs extends for 100 kb, for association with RA in NARAC II and EIRA II. Omnibus association test was used to test all haplotypes combined for association with RA. The SNP(rs3761847) was identified as a susceptible SNP for RA and verified using logestic regression analyses. Another SNP (rs2900180) was also identified as a susceptible SNP for RA. These two SNPs were in strong LD with each other (*r*^2^ = 0.62). So, the causal ungenotyped variant was considered to be in strong LD with these two polymorphisms. Interestingly, they detected a synonymous SNP in *TRAF1* gene (rs2239657) which demonstrated near perfect LD (*r*^2^ = 0.97) with (rs2900180).

The detected SNP (rs4810485) in [@b0365] was located in a haplotype block containing about the entire CD40 gene. The SNP(rs1883832) which had been associated with graves' disease, was in a very strong LD (*r*^2^ = 0.95) with (rs4810485). Another detected SNP (rs2812378) was located in a haplotype block containing the entire *CCL21* gene.

Plenge et al. [@b0340] tested a haplotype block in 6q23 region, with 20 SNPs extended for 63 kb, for association with RA cases from the Brigham RA Sequential Study (BRASS) and controls from Framingham Heart Study (FHS). Logestic regression analyses and omnibus association test were used to test all haplotypes for association with RA. Six different haplotypes, with five tag SNPs, represented 96% of the total haplotypes with a frequency of more than 0.05. The SNP(rs6920220) was identified as a susceptible SNP for RA, while SNP(rs10499194) showed a protective role against RA. Scherer et al. [@b0490] used the haplotype block, defined in [@b0340], for detecting the linkage between 6q23 region and the rate of joint destruction in early RA Dutch patients. The SNPs(rs675520G) and (rs9376293C) were identified as two susceptible alleles for increased joint destruction in ACPA-positive patients.

Zhang et al. [@b0495] promoted a GWAS based on haplotypes, extended for 1 Mb, to search for risk loci and associated genes for RA. The dataset consisted of 5,393 informative SNPs containing 822 uncorrelated individuals which were obtained from NARAC. They used FGT, CIT, solid spine of LD, and fusion of these methods to identify the haplotype blocks. Density-based clustering algorithm was used to select the final set of risk haplotypes based on the Pearson correlation coefficient for the nearest neighbor method. They detected 25 haplotypes in 18 haplotype blocks. These haplotype blocks contained 33 genes which are highly associated with the risk of RA. The genes *PTPRC* and *F12* (coagulation factor 12) prevailed the other genes in RA susceptibility.

Xie et al. [@b0335] tested three haplotype blocks in *NKAPL* region, consisted of 101 SNPs within 372 kb, for association with RA in Canadian patients. They used the CIT method to identify the haplotype blocks. Benjamini and Hochberg's false discovery rate method showed that there were six statistically significant SNPs associated with RA. These SNPs were all located in the middle haplotype block, across about 70 kb region, which contained *NKAPL*, *ZNF193*, *ZNF307*, and *ZNF187* genes. *ZNF193* (rs35656932) and *NKAPL* (rs13208096) were identified as the highest two susceptible SNPs for RA. This result was verified using stepwise and conditional logestic regression analyses.

*SE* represented a strong association with ACPA-positive RA patients. *SE* encoded consensus amino acid sequences extended from 70 to 74 positions in *HLA-DRB1*. Raychaudhuri et al. [@b0500] tried to fully explain the association with RA within MHC region in addition to *SE*. They tested 99 classical HLA alleles at two-digit resolution, 164 classical HLA alleles at four-digit resolution, 372 polymorphic amino acid positions, and 3,117 SNPs for association with ACPA-positive RA in BRASS, EIRA, NARAC I, NARAC III, WTCCC, and Canadian datasets using logistic regression. Conditional haplotype analyses uncovered new findings within the MHC region. *HLA-DRB1* codon 11, rs17878703A (a quadrallelic SNP), was identified as the highest susceptible SNP for RA. SNPs at codon 13 were in strong LD (r^2^ not specified) with those of codon 11 resulting in a double influence at this region. These findings were verified in a South Korean dataset. The two *SE* positions, 71 and 74, came after the position 11 in association with RA. Furthermore, *HLA-B* codon 9 and *HLA-DPB1* codon 9 were also associated with RA within the MHC region.

Park et al. [@b0505] explored the interaction among haplotypes through two steps. At the first step, they tested the whole genome by individual-SNP methods (codominant and additive models). Then, the haplotype blocks of the significant SNPs were identified. They used the CIT method to identify the haplotype blocks. At the second step, the interactions among haplotypes were detected using expectation maximization method and contingency table. The individual-SNP methods followed by the haplotype block method detected 411 significant SNPs and 146 haplotype blocks. Some previous detected genes that associated with RA were confirmed such as *PTPN22*, *TRAF1*, *NFKBIL1*, *HLA-C*, and *HLA-G*. Two non-synonymous SNPs showed shared mechanism of disease pathogenesis. The SNP(rs2075800) in *HSPA1L* (Heat Shock 70 kDa Protein 1-Like) was associated with both RA and sarcoidosis. The SNP(rs2476601) in *PTPN22* was associated with type I diabetes mellitus, RA, SLE, and hashimoto thyroiditis.

Most of GWAS findings in RA are because of common SNPs that do not affect protein coding regions. Diogo et al. [@b0510] identified SNPs in three genes that encode proteins that involved in RA immunopathogenesis. The three genes were *IL2RA*, *IL2RB*, and *CD2*. Then, they tried to verify the association of *CD2* with RA susceptibility using conditional haplotype analysis. They detected missense SNPs (rs798036, rs699738) and a noncoding SNP (rs624988) in *CD2* which had the best signal of association in the conditional haplotype analysis.

IL2R consists of IL2Rα (encoded by *IL2RA*), IL2Rβ (encoded by *IL2RB*), and the common gamma chain (CD132). The holding down of IL2Rα or IL2Rβ in mice leads to destructive autoimmunity. *CD2* encodes CD2 protein which is a cell-surface antigen located on T cells. The activation of regulatory T cells (through CD4^+^ and IL2Rα^+^) coactivates CD2 leading to the suppression of T cells. The regulatory T cells deal with proinflammatory processes. The regulatory T cells are functionally compromised in RA patients.

[Table 1](#t0005){ref-type="table"} summarized the detected SNPs associated with RA. [Table 1](#t0005){ref-type="table"} showed the SNP ID, the related gene, the SNP position in the genome, the used method for identification, and the studied population. The used methods for the detection of the associated SNPs were individual-SNP methods, LD, and haplotype block methods.

Studies that agree/disagree with others {#s0070}
=======================================

This section shows the studies which agree/disagree with others. The study, carried out by Gregersen et al. [@b0370], was in line with that conducted by Plenge et al. [@b0355] verifying the association of *CTLA4* with RA in North Americans. But the study carried out by Plenge et al. [@b0355] did not detect the association of *CTLA4* with RA in Swedish population, while the study carried out by Okada et al. [@b0470] confirmed the association of *CTLA4* with RA in European and Asian ancestries. The study, conducted by Chen et al. [@b0330], supported the results obtained by Raychaudhuri et al. [@b0375] for the association of *TAGAP* with RA susceptibility in European ancestry. However, *TAGAP* did not show any association with RA in African Americans through Hughes et al. [@b0435] study. The results, obtained by Raychaudhuri et al. [@b0375], contradicted the findings of Chen et al. [@b0515] for the association of *FCGR2A* with RA. This contradiction might be due to the different population ancestries (Europeans and Taiwanese) in the two studies. Also, the very small sample size used in Chen et al. study [@b0515] compared with that in Raychaudhuri et al. study [@b0375] might be the reason. Controversially, the findings of Lee et al. [@b0520] supported the findings of Chen et al. [@b0515] for the lack of association of *FCGR2A* with RA in Europeans or Asians.

The study, conducted by Kurreeman et al. [@b0380], agreed with the study carried out by Raychaudhuri et al. [@b0365] for the association of *MMEL1-TNFRSF14* with RA in European ancestry. The findings of Raychaudhuri et al. [@b0365] and Okada et al. [@b0405] supported that RA and graves' disease might have a shared mechanism of disease pathogenesis (*B3GNT2* (rs11900673), *ARID5B* (rs10821944), and *CD40* (rs1883832)). The study, carried out by Zhernakova et al. [@b0385], confirmed the results of Han et al. [@b0525] for the association of *TRAF1* with RA in European ancestry. The findings of both studies (Daha et al. [@b0530] and Zhernakova et al. [@b0385]) confirmed the association of *STAT4* with RA in European ancestry.

The *MTHFR* was confirmed for association with RA susceptibility in Jewish and Italian populations [@b0455], [@b0460]. However, the study conducted by Hughes et al. [@b0465] showed contradictory results in American Africans and Caucasians. The negative findings found in the Americans might be due to the enrichment of the flour products in the US with folic acid since 1998 [@b0460]. The *PADI4* was confirmed as an RA biomarker in the Asian populations through Too et al. [@b0450] and Suzuki et al. [@b0475] studies. Also, Plenge et al. [@b0355] detected the association of *PADI4* with RA in North Americans but not in Swedish population. The 7q region showed contradictory results for association with RA in British (females) and North American populations. These findings were found in studies performed by the WTCCC [@b0535] and Korman et al. [@b0425] respectively. The study, conducted by Hughes et al. [@b0435], was not in line with the study of Stahl et al. [@b0430] for the association of *CCR6* and *TNFAIP3* with RA in African Americans and Europeans respectively.

[Table 2](#t0010){ref-type="table"}, summarizing the above findings, showed the studies that confirm/contradict one another in the association of certain genes with RA in different ethnicities. RA biomarkers have been increased through the last decade and still increasing. To conclude, the journey to uncover all RA biomarkers seems to be endless unless large scale trans-ethnic studies take place.

Conclusions {#s0075}
===========

RA is an autoimmune disease that is considerably spread all over the world. Researchers believe that RA has genetic and environmental causes for attacking the body joints. SNPs play a vital role in shedding the light on genes and biological pathways that contribute to RA. Reviewing the literature, *HLA-DRB1* seems to be the most successful candidate for the title of RA universal biomarker depending on the large number of studies providing its association with RA patients worldwide, and even with JRA.

Most of the applied strategies on the discovery of RA biomarkers are the individual SNP approaches. Later on, the LD mapping techniques are used to detect the correlation among the studied SNP and the neighboring SNPs to identify the causal SNPs. Recently, GWAS have facilitated the empirical study of large dataset of SNPs. Then, the haplotype block methods were introduced to detect the association of RA with a whole block instead of a SNP.

Future work should concentrate on the unstudied populations, comparison among different populations, RF and CCP status, disease severity, gender related genes, JRA biomarkers, disease outcomes, response to therapies, and shared mechanism of disease pathogenesis. Extensive work in these areas should lead to understanding the etiology of RA, identification of further biological pathways, new RA drug discovery, and personal treatment of RA patients.
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![More than 35 risk loci that have been previously identified as biomarkers for RA disease [@b0050].](gr1){#f0005}

![The MHC region showing class I, class II, and class III regions [@b0195].](gr2){#f0010}

![LD structure for 12 SNPs at *HLA--DRB1* and *HLA--DPB1*. A constructed block was shown including eight SNPs, from SNP 5 to SNP 12 [@b0200].](gr3){#f0015}

![Case-control association results at 6q23. The associated SNP (rs10499194) was about 165 kb from both *TNFAIP3* and *OLIG3* genes [@b0340].](gr4){#f0020}

![Manhattan plots of the GWAS meta-analysis for RA in the Japanese population [@b0405].](gr5){#f0025}

![Manhattan plot of association with RA in the European descents [@b0440].](gr6){#f0030}

###### 

Detected SNPs associated with RA succeptibility.

  SNP          Gene                 Position         Method            Population                                                                                                                                                                                                              Comment                                                       Reference
  ------------ -------------------- ---------------- ----------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- --------------------
  rs3117213    HLA-DPB1             33,172,583       Individual-SNP    EIRA, NARAC                                                                                                                                                                                                             ACPA +                                                        [@b0200]
  rs6923005    ZNF311               29,084,051       Individual-SNP    NARAC, Wichita Rheumatic Disease Data Bank (WRDDB), the National Inception Cohort of RA Patients (NICRAP), Study of New Onset RA (SONORA)                                                                               ACPA +                                                        [@b0325]
  rs6930903    29,089,224           Individual-SNP                                                                                                                                                                                                                                                                                                           
  rs212389     TAGAP                159,068,759      Individual-SNP    BRASS, Canada, EIRA, NARAC I, NARAC III, WTCCC                                                                                                                                                                          ACPA + or RF +                                                [@b0330]
  rs2476601    PTPN22               113,834,946      Individual-SNP    EIRA, NARAC                                                                                                                                                                                                                                                                           [@b0355]
  rs2240340    PADI4                17,336,144       Individual-SNP    NARAC                                                                                                                                                                                                                                                                                 
  rs3087243    CTLA4                203,874,196      Individual-SNP    NARAC                                                                                                                                                                                                                                                                                 
  rs4810485    CD40                 44,181,354       Individual-SNP    EIRA, NARAC, WTCCC, Nurses Health Study (NHS), BRASS, NARAC II, NARAC III, Genomics Collaborative Initiative (GCI), Leiden University Medical Center (LUMC), EIRA-II, Genetics Network Rheumatology Amsterdam (GENRA)   100% (ACPA + or RF+), except for WTCCC (80% ACPA+, 84% RF+)   [@b0365]
  rs1883832    CD40                 46,118,343       LD                                                                                                                                                                                                                                                                                                      
  rs2812378    CCL21                34,700,260       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs3890745    MMEL1-TNFRSF14       2,585,786        Individual-SNP                                                                                                                                                                                                                                                                                          
  rs42041      CDK6                 91,891,395       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs4750316    PRKCQ                6,433,266        Individual-SNP                                                                                                                                                                                                                                                                                          
  rs1678542    KIF5A-PIP4K2C        56,254,982       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs13031237   REL                  60,908,994       Individual-SNP    Canada and USA (European descent)                                                                                                                                                                                       ∼95% ACPA+                                                    [@b0370]
  rs13017599   60,937,196           Individual-SNP                                                                                                                                                                                                                                                                                                           
  rs231735     CTLA4                203,829,153      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs2736340    BLK                  11,486,464       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs11586238   CD2-CD58             116,720,516      Individual-SNP    Using GRAIL (Gene Relationships Across Implicated Loci)                                                                                                                                                                                                                               [@b0375]
  rs1980422    CD28                 203,745,673      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs548234     PRDM1                106,120,159      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs394581     TAGAP                159,061,489      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs10919563   PTPRC                198,731,313      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs540386     TRAF6-RAG1           36,503,743       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs12746613   FCGR2A               161,497,252      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs3890745    MMEL1-TNFRSF14       2,585,786        Individual-SNP    European, African American, Japanese, and Korean ethnicities                                                                                                                                                                                                                          [@b0380]
  rs2872507    IKZF3-ORMDL3-GSDMB   39,884,510       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs10892279   DDX6                 118,741,072      Individual-SNP    GWAS Meta-Analysis                                                                                                                                                                                                                                                                    [@b0385]
  rs864537     CD247                167,442,147      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs2298428    UBE2L3               21,628,603       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs11203203   UBASH3A              42,416,077       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs653178     SH2B3                111,569,952      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs975730     8q24.2               128,303,768      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs1953126    TRAF1                120,878,222      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs7574865    STAT4                191,099,907      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs1051295    KCNB1                49,372,368       Individual-SNP    NARAC                                                                                                                                                                                                                                                                                 [@b0390]
  rs3087243    CTLA4                203,874,196      Individual-SNP    European Descent                                                                                                                                                                                                        GPA                                                           [@b0395]
  rs11900673   B3GNT2               62,225,526       Individual-SNP    Japanese                                                                                                                                                                                                                81.4% ACPA+, 80.4% RF+                                        [@b0405]
  rs2867461    ANXA3                78,592,061       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs657075     CSF2                 132,094,425      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs12529514   CD83                 14,096,427       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs2233434    NFKBIE               44,265,183       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs10821944   ARID5B               62,025,330       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs3781913    PDE2A-ARAP1          72,662,452       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs2841277    PLD4                 104,924,668      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs2847297    PTPN2                12,797,695       Individual-SNP                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                             
  SNP          Gene                 Position         Method            Population                                                                                                                                                                                                              Comment                                                       Reference
                                                                                                                                                                                                                                                                                                                                                             
  rs2476601    PTPN22               113,834,946      Individual-SNP    Non-hispanic white children                                                                                                                                                                                             ACPA + or RF+                                                 [@b0410]
  rs7574865    STAT4                191,099,907      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs10499194   TNFAIP3              137,681,500      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs4264222    Dectin-2             8,459,172        Individual-SNP    Caucasian (Spain and Portugal)                                                                                                                                                                                                                                                        [@b0420]
  rs4804803    DC-SIGN              7,747,847        Individual-SNP                                                                                                                                                                                                                                                                                          
  rs1024611    MCP-1                34,252,769       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs13900      34,256,892           Individual-SNP                                                                                                                                                                                                                                                                                                           
  rs4586       34,256,250           Individual-SNP                                                                                                                                                                                                                                                                                                           
  rs6859219    IL6ST                56,142,753       Individual-SNP    BRASS, CANADA, EIRA, NARAC I, NARAC III, WTCCC, CANADA II, Dutch, GENRA, GCI, LUMC, NARAC II, United Kingdom RA Genetics (UKRAG), and NHS                                                                               ACPA + or RF+                                                 [@b0430]
  rs934734     SPRED2               65,368,452       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs26232      C5orf30              103,261,019      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs874040     RBPJ                 26,106,575       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs3093023    CCR6                 167,120,802      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs10488631   IRF5                 128,954,129      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs13315591   PXK                  58,571,114       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs706778     IL2RA                6,056,986        Individual-SNP                                                                                                                                                                                                                                                                                          
  rs951005     CCL21                34,743,684       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs11676922   AFF3                 100,190,478      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs34536443   TYK2                 10,352,442       Individual-SNP    UK, EIRA, US, Dutch, Swedish Umea, Spanish, BRASS, CANADA, NARAC II, and WTCCC                                                                                                                                                                                                        [@b0440]
  rs13397      IRAK1                153,982,797      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs8026898    TLE3                 69,699,078       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs8043085    RASGRP1              38,535,939       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs2240336    PADI4                17,347,907       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs2228145    IL6R                 154,454,494      Individual-SNP                                                                                                                                                                                                                                                                                          
  rs13330176   IRF8                 85,985,481       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs12764378   ARID5B               62,040,245       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs9979383    RUNX1                35,343,463       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs12936409   IKZF3                39,887,396       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs2872507    39,884,510           Individual-SNP                                                                                                                                                                                                                                                                                                           
  rs883220     POU3F1               38,151,199       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs2834512    RCAN1                34,539,301       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs595158     CD5                  61,142,109       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs2275806    GATA3                8,053,377        Individual-SNP                                                                                                                                                                                                                                                                                          
  rs2240340    PADI4                17,336,144       Individual-SNP    Malaysian Epidemiological Investigation of RA (MyEIRA)                                                                                                                                                                                                                                [@b0450]
  rs1005753    PADI2                17,118,274       Individual-SNP                                                                                                                                                                                                                                                                                          
  rs1801131    MTHFR                11,854,476       Individual-SNP    Jewish and north Italians                                                                                                                                                                                                                                                             [@b0455], [@b0460]
  rs699738     CD2                  116,768,525      Haplotype Block   UK, EIRA, US, Dutch, Swedish Umea, Spanish, BRASS, CANADA, NARAC II, and WTCCC                                                                                                                                          ACPA +                                                        [@b0510]
  rs624988     116,721,168                                                                                                                                                                                                                                                                                                                                   
  rs798036     116,766,208                                                                                                                                                                                                                                                                                                                                   
  rs11203366   PADI4                17,331,039       Haplotype Block   Japanese                                                                                                                                                                                                                75% RF+                                                       [@b0475]
  rs11203367   17,331,121                                                                                                                                                                                                                                                                                                                                    
  rs874881     17,334,004                                                                                                                                                                                                                                                                                                                                    
  rs1748033    17,336,167                                                                                                                                                                                                                                                                                                                                    
  rs17878703   HLA--DRB1            32,584,360       Haplotype Block   BRASS, CANADA, EIRA, NARAC I, NARAC III, WTCCC                                                                                                                                                                          ACPA+                                                         [@b0500]
  rs13195291   ZNF193               28,201,463       Haplotype Block   Canada, USA (European Ancestry)                                                                                                                                                                                         [@b0335]                                                      
  rs35656932   28,223,510                                                                                                                                                                                                                                                                                                                                    
  rs13204012   28,233,753                                                                                                                                                                                                                                                                                                                                    
  rs17720293   ZNF307               28,246,920                                                                                                                                                                                                                                                                                                               
  rs13208096   NKAPL                28,257,533                                                                                                                                                                                                                                                                                                               
  rs67998226   ZNF187               28,270,281                                                                                                                                                                                                                                                                                                               
  rs6920220    TNFAIP3-OLIG3        137,685,367      Haplotype Block   BRASS, FHS, NARAC I, EIRA                                                                                                                                                                                               ACPA +                                                        [@b0340]
  rs10499194   137,681,500                                                                                                                                                                                                                                                                                                                                   
  rs3761847    TRAF1                120,927,961      Haplotype Block   NARAC I, NARAC II, EIRA I, EIRA II                                                                                                                                                                                      ACPA +                                                        [@b0485]
  rs2900180    TRAF1-C5             120,944,104                                                                                                                                                                                                                                                                                                              
  rs2239657    TRAF1                120,909,242      LD                                                                                                                                                                                                                                                                                                      

###### 

Studies that agree/disagree with other studies.

  Gene             Confirmed in                                     Not detected in                       References
  ---------------- ------------------------------------------------ ------------------------------------- ------------------------------
  CTLA4            North Americans, European and Asian ancestries   Swedish                               [@b0355], [@b0370], [@b0470]
  TAGAP            European ancestry                                African Americans                     [@b0330], [@b0375], [@b0435]
  FCGR2A           Europeans                                        Taiwanese, Europeans or Asians        [@b0375], [@b0515], [@b0520]
  MMEL1-TNFRSF14   European ancestry                                --                                    [@b0365], [@b0380]
  TRAF1            European ancestry                                --                                    [@b0385], [@b0525]
  STAT4            European ancestry                                --                                    [@b0385], [@b0530]
  PADI4            North Americans and Asians                       Swedish                               [@b0355], [@b0450], [@b0475]
  7q               British females                                  North Americans                       [@b0425], [@b0535]
  CCR6             Europeans                                        African Americans                     [@b0430], [@b0435]
  TNFAIP3                                                                                                 
  MTHFR            Jewish and Italians                              Americans (Africans and Caucasians)   [@b0455], [@b0460], [@b0465]
